相关实验视频
Updated: Jun 16, 2026

08:28
Monitoring the Wall Mechanics During Stent Deployment in a Vessel
Published on: May 8, 2012
释放药物的支架和冠状动脉血栓症:生物机制和临床影响
Thomas F Lüscher1, Jan Steffel, Franz R Eberli
1Cardiovascular Center, University of Zurich, Rämistrasse 100, 8091 Zürich, Switzerland. cardiotfl@gmx.ch
Circulation
|February 28, 2007
概括
药物排泄支架 (DES) 可以导致支架血栓形成,这是一个严重的并发症. 虽然证据是不确定的,但像支架设计和抗血小板药物过早停止等因素会增加风险,需要进一步研究.
科学领域:
- 心血管医学 心血管医学
- 干预心脏病学 干预心脏病学
- 生物材料科学 生物材料科学
背景情况:
- 支架血栓是支架植入后的一种罕见但严重的并发症,与裸金属支架相比,药物排泄支架 (DES) 的发病率更高.
- 导致支架血栓形成的因素包括程序问题,患者特征,支架设计和过早停止抗血小板治疗.
- 在DES中的药物和聚合物的生物效应可能会损害再内皮细胞化,并促进前血栓性环境,可能增加血栓形成的风险.
研究的目的:
- 审查支架血栓的病理生理机制和病理发现,特别是在药物释放支架 (DES) 中.
- 综合有关DES血栓形成风险的现有证据,并确定相关的促成因素.
- 突出进一步进行大规模临床试验和机制研究的需要,以澄清DES血栓形成风险.
主要方法:
- 现有文献的审查,包括大型注册表,随机试验的元分析和机制研究.
- 对涉及DES诱导的支架血栓形成的病理生理路径的分析.
- 检查与DES中的支架血栓相关的病理发现.
主要成果:
- DES可能会增加支架血栓形成的风险,原因是受损的再内皮质化,延迟的动脉愈合,以及诱导的血栓生成环境.
- 支架错位,不充分扩张,多支架,支架长度,慢动脉流动,剖析,患者因素和抗血小板药物过早停止都与风险增加有关.
- 关于绝对更高的DES血栓形成风险的证据仍然不确定,这强调需要更多的研究.
结论:
- 药物排泄支架 (DES) 呈现复杂的病理生理机制,可能导致支架血栓形成.
- 虽然已确定了促成因素,但与裸金属支架相比,DES血栓形成的整体风险需要进一步调查.
- 额外的大规模,长期的临床试验和机制研究对于最终评估和理解DES相关的支架血栓形成至关重要.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...

